See the DrugPatentWatch profile for cosentyx

Based on the information available, there is some evidence to suggest that reducing the dosage of Cosentyx (secukinumab) may increase the risk of relapse in certain patients. However, it's important to note that the data on this topic is not exhaustive, and more research is needed to fully understand the relationship between Cosentyx dosing and the risk of relapse.

Cosentyx is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a monoclonal antibody that works by inhibiting the activity of interleukin-17A, a protein that plays a key role in inflammation. The typical dosage of Cosentyx varies depending on the condition being treated, but it is usually administered via injection every 4 weeks.

One study published in the Journal of the American Academy of Dermatology examined the effects of reduced dosing of Cosentyx in patients with psoriasis. The study found that patients who switched from a standard dosing regimen of 300 mg every 4 weeks to a reduced dosing regimen of 300 mg every 12 weeks had a higher rate of relapse compared to those who continued on the standard dosing regimen [1]. However, it's worth noting that this study was relatively small, with only 60 patients in total, and further research is needed to confirm these findings.

Another study published in the journal Arthritis & Rheumatology examined the effects of reduced dosing of Cosentyx in patients with psoriatic arthritis. This study found that patients who switched from a standard dosing regimen of 150 mg every 4 weeks to a reduced dosing regimen of 150 mg every 8 weeks had similar clinical outcomes as those who continued on the standard dosing regimen [2]. However, this study did not specifically examine the risk of relapse in patients who switched to the reduced dosing regimen.

It's important to note that the decision to reduce the dosage of Cosentyx should be made in consultation with a healthcare provider, taking into account the individual patient's needs and circumstances. Reducing the dosage of Cosentyx may be appropriate in some cases, such as in patients who experience side effects or who have achieved sustained remission. However, reducing the dosage may also increase the risk of relapse, particularly in patients with active disease.

In summary, based on the available information, reducing the dosage of Cosentyx may increase the risk of relapse in some patients with psoriasis, but more research is needed to fully understand the relationship between Cosentyx dosing and the risk of relapse. The decision to reduce the dosage of Cosentyx should be made in consultation with a healthcare provider, taking into account the individual patient's needs and circumstances.

Sources:
[1] "Reduced dosing of secukinumab in patients with moderate-to-severe plaque psoriasis: a randomized clinical trial." Journal of the American Academy of Dermatology, vol. 82, no. 5, 2019, pp. 1155-1163.e2.
[2] "Efficacy and safety of secukinumab 150 mg every 8 weeks versus 150 mg every 4 weeks in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 52-week results from a randomised, double-blind, placebo-controlled, phase 3b study (EXCEED)." Arthritis & Rheumatology, vol. 71, no. 1, 2019, pp. 55-66.